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ABSTRACT
Background. The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry collects
data on kidney replacement therapy (KRT) via national and regional renal registries in Europe and countries bordering the
Mediterranean Sea. This article summarizes the 2018 ERA-EDTA Registry Annual Report, and describes the epidemiology of
KRT for kidney failure in 34 countries.
Methods. Individual patient data on patients undergoing KRT in 2018 were provided by 34 national or regional renal registries
and aggregated data by 17 registries. The incidence and prevalence of KRT, the kidney transplantation activity and the
survival probabilities of these patients were calculated.
Results. In 2018, the ERA-EDTA Registry covered a general population of 636 million people. Overall, the incidence of KRT for
kidney failure was 129 per million population (p.m.p.), 62% of patients were men, 51% were 65 years of age and 20% had






/ckj/article/14/1/107/6046935 by guest on 15 February 2021
diabetes mellitus as cause of kidney failure. Treatment modality at the onset of KRT was haemodialysis (HD) for 84%,
peritoneal dialysis (PD) for 11% and pre-emptive kidney transplantation for 5% of patients. On 31 December 2018, the
prevalence of KRT was 897 p.m.p., with 57% of patients on HD, 5% on PD and 38% living with a kidney transplant. The
transplant rate in 2018 was 35 p.m.p.: 68% received a kidney from a deceased donor, 30% from a living donor and for 2% the
donor source was unknown. For patients commencing dialysis during 2009–13, the unadjusted 5-year survival probability
was 42.6%. For patients receiving a kidney transplant within this period, the unadjusted 5-year survival probability was
86.6% for recipients of deceased donor grafts and 93.9% for recipients of living donor grafts.
Keywords: dialysis, epidemiology, kidney failure, kidney transplantation, survival analysis
INTRODUCTION
This article summarizes the European Renal Association –
European Dialysis and Transplant Association (ERA-EDTA)
Registry’s 2018 Annual Report, providing the most recent data
on the epidemiology of kidney replacement therapy (KRT) for
kidney failure in Europe, and countries bordering the
Mediterranean Sea [1]. In total, 51 national or regional renal reg-
istries from 34 countries provided data to the ERA-EDTA
Registry, of which 34 renal registries from 18 countries provided
individual patient data, and another 17 renal registries provided
aggregated data from 17 countries (Supplementary Appendix
S1). In total, these registries cover a general population of 636
million people, which is lower than the 694 million people
covered in the 2017 Annual Report [2], as this year Croatia,
Georgia, Poland and Sfax region (Tunisia) could not be included.
When excluding Israel, the remaining countries cover a general
population of 627 million people, representing 74.2% of the
total 2018 European general population. On the other hand,
compared with our 2017 Annual Report, Montenegro and the
Valencian region (Spain) are now included with individual
patient data.
This article presents the 2018 incidence and prevalence of
KRT, kidney transplantation activity and both patient and graft
survival in Europe. More information on the methods used to
analyse the data, as well as the complete results, can be found
in the ERA-EDTA Registry 2018 Annual Report [1].
RESULTS
Incidence of KRT
In 2018, 81 714 individuals out of a population of 636 million peo-
ple started KRT for kidney failure, resulting in an overall unad-
justed incidence of 129 per million population (p.m.p.; Table 1).
The unadjusted incidence ranged from 37, 73 and 74 p.m.p. in
Ukraine, Estonia and Montenegro, respectively, to 256 p.m.p. in
Portugal and Cyprus and 264 p.m.p. in Greece (Table 1 and
Figures 1 and 2). Of the patients starting KRT, 62% were men, 51%
were aged 65 years and 20% had diabetes mellitus (DM) as cause
of kidney failure (Figure 3). The median age of the patients start-
ing KRT was 66.5 years, and differed by almost 20 years between
Ukraine (55.0 years) and the Dutch-speaking part of Belgium
(74.4 years; Table 1). The majority (84%) of patients started KRT
with haemodialysis (HD), another 11% started with peritoneal di-
alysis (PD) and 5% of patients received a pre-emptive kidney
transplant (Figure 4). While the distribution of initial treatment
modalities was similar for men and women, there were consider-
able differences between age groups, with decreasing proportions
of patients receiving either PD or a pre-emptive transplant with
increasing age (Figure 4). In addition, compared with patients
without DM as cause of kidney failure, those with DM as cause of
kidney failure more often started KRT on HD (85% versus 80%),
and less frequently received a pre-emptive kidney transplant (2%
versus 6%). Among the incident patients receiving KRT at Day 91
after the onset of treatment, 82% were receiving HD, 13% were re-
ceiving PD and 5% were living with a functioning kidney trans-
plant (Figure 5). When compared with Day 1, the percentage of
patients receiving HD decreased, a finding that was particularly
evident in the younger age groups.
Prevalence of KRT
On 31 December 2018, 569 678 patients were receiving KRT
for kidney failure, corresponding to an overall unadjusted
prevalence of 897 p.m.p. (Table 2). Among the individual coun-
tries or regions the unadjusted prevalence ranged from 229,
313 and 411 p.m.p. in Ukraine, Montenegro and Russia, respec-
tively, to 1469, 1547 and 2011 p.m.p. in Catalonia (Spain),
Valencian region (Spain) and Portugal, respectively (Table 2
and Figures 6 and 7). Of the prevalent patients, 60% were men,
43% were aged 65 years and 15% had DM as cause of kidney
failure (Figure 8). The median age of prevalent patients receiv-
ing KRT was 63.0 years, ranging from 52.0 years in Albania
and Ukraine to 68.6 years in Israel (Table 2). Of the prevalent
patients, 57% were receiving HD and 5% were receiving PD,
while 38% were living with a kidney transplant (Figure 9).
Compared with prevalent patients with a cause of kidney
failure other than DM, those with DM as cause of kidney fail-
ure were less likely to be living with a functioning kidney
transplant (51% versus 29%).
Kidney transplantation
In 2018, a total of 22 260 kidney transplantations were performed,
corresponding to an overall unadjusted transplant rate of 35
p.m.p. (Figure 10). In the individual countries or regions, the unad-
justed kidney transplant rates ranged from 3 p.m.p. in Ukraine
and 4 p.m.p. in Bulgaria and Serbia, to 76, 77 and 102 p.m.p. in
Asturias (Spain), Cantabria (Spain) and Catalonia (Spain), respec-
tively. Overall, the unadjusted deceased donor kidney transplant
rate was more than twice that of living donor transplants (24
p.m.p. versus 10 p.m.p.; 68% versus 30%; Figures 11 and 12). The
highest unadjusted rates of deceased donor kidney transplants
were observed in several Spanish regions (>70 p.m.p.; Figure 12),
whereas the highest unadjusted rates of living donor transplants
were observed in Northern Ireland (27 p.m.p.), the Netherlands
(28 p.m.p.) and Turkey (37 p.m.p.; Figure 12).
Survival of patients receiving KRT
For patients commencing KRT in the period 2009–13, the 5-year
unadjusted patient survival probability was 51.1% [95% confi-
dence interval (95% CI) 51.0–51.2; Table 3]. For patients starting
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Table 1. Incidence of KRT (as count and p.m.p.) in 2018, at Day 1, by country or region, unadjusted and the mean and median age at the start













age (years) DM (n)
DM
(p.m.p.)
Albania 2841 398 140 59.8 61.0 78 27
Austria 8822 1057 120 64.4 67.1 243 28
Belarus 9475 782 83 176 19
Belgium, Dutch-speakinga 6578 1186 180 71.1 74.4 241 37
Belgium, French-speakinga 4849 983 203 68.6 70.0 187 39
Bosnia and Herzegovina 3531 440 125 62.0 64.0 127 36
Bulgaria 7000 1091 156 317 45
Cyprus 876 224 256 69.0 73.0 86 98
Czech Republicb 9983 2265 227
Denmark 5850 679 116 63.2 66.8 174 30
Estonia 1322 96 73 57.3 58.5 20 15
Finland 5516 509 92 61.1 64.1 161 29
France 66 966 11 296 169 67.6 70.5 2503 37
Greece 10 733 2833 264 70.9 73.5 682 64
Iceland 353 28 79 59.7 59.6 5 14
Israel 8883 1723 194 65.4 68.1 780 88
Italy (7 of 20 regions) 21 427 3355 157 68.6 71.6 559 26
Kosovo 1688 295 175 62.0 65.0 112 66
Latvia 1312 141 107 62.3 66.0 28 21
Lithuania 2809 316 112 59.9 60.4 46 16
Montenegroa 622 46 74 56.5 60.1 10 16
North Macedonia 2022 339 168 62.9 64.0 104 51
Norway 5312 546 103 63.8 67.9 92 17
Portugal 10 309 2634 256 811 79
Romania 19 064 3487 183 62.5 64.5 424 22
Russiab 133 570 11 070 83 56.3 61.0 1838 14
Serbia 6284 552 88 61.0 63.6 124 20
Slovakiab 5444 898 165 64.5 66.0 325 60
Spain (All) 46 723 6918 148 64.8 68.2 1702 36
Spain, Andalusia 8419 1221 145 62.5 65.5 319 38
Spain, Aragon 1317 141 107 66.8 69.8 33 25
Spain, Asturias 1028 172 167 67.2 68.5 53 52
Spain, Basque country 2174 251 115 65.2 68.4 61 28
Spain, Canary Islands 2192 382 174 64.3 66.4 136 62
Spain, Cantabriaa 581 88 151 69.4 72.1 12 21
Spain, Castile and Leóna 2409 345 143 66.3 69.4 81 34
Spain, Castile-La Manchaa 2034 243 119 66.7 69.5 67 33
Spain, Catalonia 7600 1392 183 65.8 69.6 275 36
Spain, Community of Madrid 6578 915 139 65.6 69.2 241 37
Spain, Extremadura 1073 158 147 64.5 66.4 41 38
Spain, Galicia 2702 397 147 65.3 67.9 103 38
Spain, Murcia 1479 221 149 62.1 65.4 54 37
Spain, Navarrea 647 71 110 67.4 70.4 16 25
Spain, Valencian region 4964 783 158 66.2 70.0 166 33
Sweden 10 175 1095 108 64.2 68.1 280 28
Switzerland 8514 875 103 65.5 69.3 192 23
The Netherlands 16 025 1975 123 63.9 67.2 380 24
Turkeyc 82 004 12 232 149 954 54
Ukraine 42 216 1563 37 52.8 55.0 370 9
UK, Englanda,d 55 977 6530 117 62.0 64.0 1761 31
UK, Northern Irelanda 1882 228 121 64.3 67.2 48 26
UK, Scotland 5438 613 113 60.2 62.1 180 33
UK, Walesa 3139 416 133 63.4 65.9 125 40
All countries 635 534 81 714 129 63.5 66.5 16 245 29
When cells are left empty, the data are unavailable and could not be used for the calculation of the summary data.
aPatients <20 years are not reported. The true incidence counts are therefore slightly higher than the counts reported here.
bData include dialysis patients only.
cData on incidence by cause of kidney failure (DM) is based on 2642 dialysis patients (21.6% of total).
dThe incidence is underestimated by 2% due to one centre not submitting data since 2014.
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KRT with dialysis in this period, the unadjusted 5-year patient
survival probability was 42.6% (95% CI 42.5–42.7). Adjusted anal-
yses for patient survival on HD and PD revealed higher survival
probabilities in the first 3 years for those receiving PD
(Figure 13). For patients receiving a kidney transplant in the pe-
riod 2009–13, living donor transplant recipients experienced a
higher adjusted 5-year patient survival than recipients of de-
ceased donor transplants: 94.7% (95% CI 94.3–95.2) versus 92.0%
FIGURE 1: Incidence of KRT (p.m.p.) in 2018, at Day 1, by country or region, unadjusted. The incidence for Czech Republic, Russia and Slovakia only includes patients re-
ceiving dialysis. For England (UK), the incidence is underestimated by 2% (Table 1).
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(95% CI 91.7–92.3; Figure 13), as well as a higher adjusted 5-year
graft survival: 87.1% (95% CI 86.4–87.8) versus 81.1% (95% CI
80.6–81.5; Table 3). A description of the adjustments made and
the countries and regions included in these analyses can be
found in Table 3.
Expected remaining lifetime
Patients receiving dialysis between 2014 and 2018 are expected
to live only half of the estimated expected remaining lifetime of
patients living with a functioning kidney transplant in the same
period (Figure 14). When compared with the general population,
FIGURE 2: Unadjusted (left panel) and adjusted (right panel) incidence of KRT p.m.p. in 2018, at Day 1, by country or region. Registries providing individual patient data
are shown as dark bars, and registries providing aggregated data as light bars. Adjustment of incidence was performed by standardizing to the age and sex distribution
of the EU27 population. The incidence for Czech Republic, Russia and Slovakia only includes patients receiving dialysis. For England (UK), the incidence is underesti-
mated by 2% (Table 1).
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the life expectancy of patients on dialysis was 70% shorter,
while for kidney transplant recipients it was 40% shorter.
AFFILIATED REGISTRIES
Albanian Renal Registry (A. Idrizi, M. Rroji and E. Likaj); Austrian
Dialysis and Transplant Registry (OEDTR) (F. Engler, J.
Kerschbaum, R. Kramar, G. Mayer and the Austrian Society of
Nephrology); Belarus Renal Registry (K.S. Komissarov, K.S.
Kamisarau and A.V. Kalachyk); Dutch speaking Belgian Society
of Nephrology (NBVN) (M. Couttenye, F. Schroven and J. De
Meester); French speaking Belgian Society of Nephrology (GNFB)
(J.M. des Grottes and F. Collart); Renal Registry Bosnia and
Herzegovina (H. Resic, B Jakovljevic and Z. Kelava); Bulgaria
FIGURE 3: (A) Sex, (B) age and (C) cause of kidney failure distribution by type of data provided for incident patients accepted for KRT in 2018, at Day 1. See
Supplementary Appendix A1 for a list of countries and regions providing individual patient data or aggregated data.
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FIGURE 4: Treatment modality distribution, at Day 1, by (A) type of data pro-
vided, (B) age, (C) sex and (D) cause of kidney failure (DM and non-DM) for inci-
dent patients accepted for KRT in 2018. Parts (B), (C) and (D) are only based on
the data from registries providing individual patient data. See Supplementary
Appendix A1 for a list of countries and regions providing individual patient data
or aggregated data. Tx, kidney transplant
FIGURE 5: Treatment modality distribution, at Day 91, by (A) type of data pro-
vided, (B) age, (C) sex and (D) cause of kidney failure (DM and non-DM) for inci-
dent patients accepted for KRT in 2018. Parts (B), (C) and (D) are only based on
the data from registries providing individual patient data. See Supplementary
Appendix A1 for a list of countries and regions providing individual patient data
or aggregated data. Tx, kidney transplant
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Table 2. Prevalence of KRT (as count and p.m.p.) on 31 December 2018, by country or region, unadjusted and the mean and median age on 31
















Albania 2841 1602 564 51.3 52.0 322 113
Austria 8822 9577 1086 62.0 63.4 1756 199
Belarus 9475 4096 432 541 57
Belgium, Dutch-speakinga 6578 8466 1287 66.4 68.4 1435 218
Belgium, French-speakinga 4849 6559 1353 65.2 66.9 1164 240
Bosnia and Herzegovina 3531 2699 764 59.9 61.6 539 153
Bulgaria 7000 4464 638
Cyprus 876
Czech Republic 9983 12 194 1221
Denmark 5850 5541 947 59.1 60.7 938 160
Estonia 1322 983 744 58.3 59.0 176 133
Finland 5516 5106 926 59.6 62.1 1286 233
France 66 966 90 358 1349 63.2 65.3 14 881 222
Greece 10 733 14 665 1366 65.4 67.5 2757 257
Iceland 353 266 754 56.3 57.5 30 85
Israelb 8883 6747 760 66.6 68.6 3121 351
Italy (7 of 20 regions) 21 427 26 131 1220 62.8 65.0 2916 136
Kosovo 1688 805 477 62.9 66.0 240 142
Latvia 1312 1020 778 55.5 57.0 103 79
Lithuania 2809 2342 834
Montenegroa 622 195 313 57.0 59.5 28 45
North Macedonia 2022 1756 868 58.8 60.0 304 150
Norway 5312 5256 989 60.0 62.2 724 136
Portugal 10 309 20 730 2011 68.0 68.5 3670 356
Romania 19 064 21 738 1140 62.6 64.3 2220 116
Russia 133 570 54 953 411 56.8 59.0 7913 59
Serbia 6284 4589 730 60.0 62.4 808 129
Slovakiab 5444 3589 659 64.1 66.0 1202 221
Spain (All) 46 723 61 773 1322 59.9 63.1 10 014 214
Spain, Andalusia 8419 10 577 1256 60.9 62.2 1675 199
Spain, Aragon 1317 1710 1299 63.8 65.2 307 233
Spain, Asturias 1028 1409 1371 63.9 65.1 252 245
Spain, Basque country 2174 2723 1252 62.2 64.4 328 151
Spain, Canary Islands 2192 3200 1460 61.8 63.1 886 404
Spain, Cantabriaa 581 689 1185 63.4 64.7 97 167
Spain, Castile and Leóna 2409 3126 1298 65.4 66.5 552 229
Spain, Castile-La Manchaa 2034 2485 1222 63.3 64.1 405 199
Spain, Catalonia 7600 11 162 1469 63.3 65.0 1609 212
Spain, Community of Madrid 6578 7816 1188 62.3 63.8 1406 214
Spain, Extremadura 1073 1326 1236 62.4 62.8 207 193
Spain, Galicia 2702 3816 1412 63.1 64.5 649 240
Spain, Murcia 1479 2043 1382 62.4 63.3 299 202
Spain, Navarrea 647 865 1337 63.2 65.0 128 198
Spain, Valencian region 4964 7679 1547 63.5 65.5 1095 221
Sweden 10 175 10 206 1003 60.3 62.4 1836 180
Switzerland 8514 8077 949 62.5 64.5 1220 143
The Netherlands 16 542 17 493 1057 60.8 62.8 2336 141
Turkeyc 82 004 81 055 988 3043 338
Ukraine 42 216 9659 229 50.7 52.0 1511 36
UK, Englanda,d 55 977 54 520 974 59.0 59.6 9645 172
UK, Northern Irelanda 1882 1909 1015 59.3 59.5 283 150
UK, Scotland 5438 5324 979 57.1 58.5 901 166
UK, Walesa 3139 3235 1031 59.6 60.7 561 179
All countries 636 051 569 678 897 61.1 63.0 80 424 148
When cells are left empty, the data are unavailable and could not be used for the calculation of the summary data.
aPatients <20 years are not reported. The true prevalent counts are therefore slightly higher than the counts reported here.
bData on prevalence include dialysis patients only.
cData on the prevalence by cause of kidney failure (DM) is based on 8904 dialysis patients (11.0% of total).
dThe prevalence is underestimated by 1% due to one centre not submitting data since 2014.
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(E.S. Vazelov and I. Velinova); Cyprus Renal Registry (K. Ioannou
and all of the renal units providing data); Czech Republic:
Registry of Dialysis Patients (RDP) (F. Lopot, I. Rychlı́k and J.
Potucek); Danish Nephrology Registry (DNS) (K. Hommel);
Estonian Society of Nephrology (Ü. Pechter, K. Lilienthal and
M. Rosenberg); Finnish Registry for Kidney Diseases (P. Finne
and J. Helve); France: The Epidemiology and Information
Network in Nephrology (REIN) (M. Lassalle and C. Couchoud);
Hellenic Renal Registry (G. Moustakas); Icelandic End-Stage
Renal Disease Registry (R. Pálsson); Montenegro Renal Registry
FIGURE 6: Prevalence of KRT (p.m.p.) on 31 December 2018 by country or region. The prevalence for Israel and Slovakia only includes patients receiving dialysis. For
England (UK), the prevalence is underestimated by 1% (see Table 2).
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(M. Ratkovic, D. Radunovic and F. Tomovic); Israel National
Registry of Renal Replacement Therapy (R. Dichtiar, L. Keinan-
Boker and E. Golan); Italian Registry of Dialysis and
Transplantation (RIDT) (A. Limido, M. Nordio and M. Postorino);
Kosovo Renal Registry (H. Korca, S. Selmani and M. Tolaj-Avdiu);
Latvian Renal Registry (V. Kuzema, H. Cernevskis and A.
Popova); Lithuanian Renal Registry (V. Vainauskas, K. Petruliene
and E. Ziginskiené); North Macedonian Renal Registry (N.
Gjorgjievski, O. Stojceva and B.I. Rambabova); Norwegian Renal
Registry (A.V. Reisæter and A. Åsberg); Portuguese Renal
Registry (A. Galv~ao and A. Ferreira); Romanian Renal Registry
(G. Mircescu, L. Garneata and E. Podgoreanu); Russian Renal
Registry (N. Tomilina, H. Zakharova and A. Andrusev); Renal
Registry in Serbia (M. Lausevic, R. Naumovic and all of the
Serbian renal units and the Serbian Society of Nephrology);
Slovakian Renal Registry (V. Spustová, I. Lajdová and M.
FIGURE 7: Unadjusted (left panel) and adjusted (right panel) prevalence (p.m.p.) of KRT on 31 December 2018 by country or region. Registries providing individual pa-
tient data are shown as dark bars, and registries providing aggregated data as light bars. Adjustment of the prevalence was performed by standardizing to the age and
sex distribution of the EU27 population. The prevalence for Israel and Slovakia only includes patients receiving dialysis. For England (UK), the prevalence is underesti-
mated by 1% (see Table 2).
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Karolyova); Spain Renal Registry (B. Mahillo Durán and Spanish
Regional Registries); Swedish Renal Registry (K.G. Prütz, M.
Stendahl, M. Evans, S. Schön, T. Lundgren, H. Rydell and M.
Segelmark); Swiss Dialysis Registry (P. Ambühl and R. Winzeler);
Dutch Renal Registry (RENINE) (L. Heuveling, S. Vogelaar and M.
Hemmelder); Registry of the Nephrology, Dialysis and
Transplantation in Turkey (TSNNR) (G. Süleymanlar, N. Seyahi
and K. Ateş); Ukrainian Renal Data System (M. Kolesnyk, O.
Razvazhaieva and N. Kozliuk); UK Renal Registry (all the staff of
the UK Renal Registry and of the renal units submitting data);
FIGURE 8: (A) Sex, (B) age and (C) cause of kidney failure distribution, by type of data provided for prevalent patients on KRT on 31 December 2018. See Supplementary
Appendix A1 for a list of countries and regions providing individual patient data or aggregated data.
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Scottish Renal Registry (SRR) (all of the Scottish renal units); and
the regional registries of Andalusia (SICATA) (P. Castro de la
Nuez (on behalf of all users of SICATA), Aragon (F. Arribas
Monzón), Asturias (P. Beltrán, M. Rodrı́guez, J.R. Quirós and
RERCA Working Group), Basque country (UNIPAR) (Á. Magaz, J.
Aranzabal, M. Rodrigo and I. Moina), Canary Islands (S. Trujillo
Alemán, I. Santana Gil and C. Torres Medina), Cantabria (J.C.
Ruiz San Millán), Castile and León (M.A. Palencia Garcı́a and P.
Ucio Mingo), Castile-La Mancha (G. Gutiérrez Ávila and I.
Moreno Alı́a), Catalonia (RMRC) (J. Comas and J. Tort),
Community of Madrid (M.I. Aparicio de Madre and F Tornero
Molina), Extremadura [all the renal units (Nephrology and
Dialysis)], Galicia (E. Bouzas-Caama~no), Renal Registry of the
Region of Murcia (I. Marı́n Sánchez and C. Santiuste de Pablos),
Navarre (M.F. Slon Roblero, J. Manrique Escola and J. Arteaga
Coloma) and Valencian region (A. Bernat Hoyos and O.
Zurriaga).
ERA-EDTA REGISTRY COMMITTEE MEMBERS
C. Wanner, Germany (ERA-EDTA President); Z.A. Massy, France
(Chairman); P. Ambühl, Switzerland; M. Arici, Turkey; M. Evans,
Sweden; P. Finne, Finland; J. Harambat, France; J. de Meester,
Belgium; L. Mercadal, France; M. Nordio, Italy; S.S. Sørensen,
Denmark; and E. Vidal, Italy.
ERA-EDTA REGISTRY OFFICE STAFF
K.J. Jager (Managing Director), M. Bonthuis (for the paediatric
section), R. Boenink, J.R. Bosdriesz, R. Cornet, G. Guggenheim,
A.L.C.J.R.M. Huijben, A. Kramer, V.S. Stel and A.J. Weerstra.
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Supplementary data are available at ckj online.
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FIGURE 9: Treatment modality distribution by (A) type of data provided, (B) age,
(C) sex and (D) cause of kidney failure (DM and non-DM) for prevalent patients
on KRT on 31 December 2018. Parts (B), (C) and (D) are only based on the data
from registries providing individual patient data. See Supplementary Appendix
A1 for a list of countries and regions providing individual patient data or aggre-
gated data. Tx, kidney transplant
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FIGURE 10: Kidney transplants performed in 2018, presented as counts and p.m.p. (unadjusted) by country or region. Registries providing individual patient data are
shown as red bars, and registries providing aggregated data as orange bars. The total count for Austria is based on residents and non-residents. For Romania, Serbia
and England (UK), the overall kidney transplant rate is underestimated by 30, 15 and 7%, respectively.
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FIGURE 11: Donor-type distribution for kidney transplants performed in 2018, by type of data provided. See Supplementary Appendix A1 for a list of countries and
regions providing individual patient data or aggregated data.
FIGURE 12: Deceased donor (A) and living donor (B) kidney transplants performed in 2018 p.m.p., by country or region, unadjusted. Registries providing individual pa-
tient data are shown as dark bars and registries providing aggregated data as light bars. The total count for Austria is based on residents and non-residents. For
Romania and England (UK), the kidney transplant rate is underestimated by 30 and 7%, respectively. For Serbia, the transplant rate is underestimated by 16% for de-
ceased donor transplants and by 12% for living donor transplants.
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Table 3. The survival probabilities at 1, 2 and 5 years by treatment modality and cohort, from Day 1 of the start of KRT, dialysis or from the day
of kidney transplantation
Survival probabilities as percentage (95% CIs)
Cohort: 2009–13 Cohort: 2012–16
Survival type 1 year 2 years 5 years 1 year 2 years
Patient survival on KRT
Unadjusted 84.3 (84.2–84.5) 74.3 (74.2–74.5) 51.1 (51.0–51.2) 85.1 (85.0–85.3) 75.1 (75.0–75.3)
Adjusteda 87.0 (86.9–87.2) 77.9 (77.6–78.1) 53.1 (52.8–53.4) 87.5 (87.4–87.7) 78.3 (78.1–78.5)
Patient survival on dialysis
Unadjusted 83.3 (83.1–83.4) 71.8 (71.7–72.0) 42.6 (42.5–42.7) 84.1 (83.9–84.2) 72.6 (72.4–72.7)
Adjusteda 85.5 (85.3–85.6) 75.1 (74.9–75.3) 46.4 (46.1–46.8) 86.3 (86.1–86.5) 76.0 (75.8–76.3)
Patient survival after first kidney transplantation (deceased donor)
Unadjusted 96.1 (95.9–96.3) 94.0 (93.8–94.2) 86.6 (86.3–86.9) 96.3 (96.1–96.4) 94.1 (93.9–94.3)
Adjustedb 97.8 (97.7–97.9) 96.5 (96.4–96.7) 92.0 (91.7–92.3) 98.0 (97.8–98.1) 96.8 (96.6–96.9)
Graft survival after first kidney transplantation (deceased donor)
Unadjusted 90.7 (90.5–91.0) 87.6 (87.3–87.9) 77.5 (77.2–77.9) 91.2 (90.9–91.4) 88.0 (87.7–88.3)
Adjustedb 92.4 (92.1–92.6) 89.7 (89.4–90.0) 81.1 (80.6–81.5) 93.0 (92.7–93.2) 90.4 (90.1–90.7)
Patient survival after first kidney transplantation (living donor)
Unadjusted 98.9 (98.7–99.1) 97.9 (97.6–98.2) 93.9 (93.5–94.3) 98.9 (98.7–99.1) 98.0 (97.8–98.3)
Adjustedb 99.1 (98.9–99.2) 98.2 (98.0–98.5) 94.7 (94.3–95.2) 99.1 (98.9–99.2) 98.3 (98.1–98.5)
Graft survival after first kidney transplantation (living donor)
Unadjusted 96.5 (96.2–96.8) 94.7 (94.3–95.1) 87.8 (87.2–88.3) 96.7 (96.4–97.0) 95.1 (94.8–95.5)
Adjustedb 96.3 (95.9–96.6) 94.4 (94.0–94.9) 87.1 (86.4–87.8) 96.5 (96.2–96.8) 94.8 (94.4–95.2)
The findings are based on data from the following renal registries providing individual patient data: Austria, Belgium (Dutch-speaking), Belgium (French-speaking),
Bosnia and Herzegovina, Denmark, Finland, France, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain
(Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Community of Madrid), Spain (Extremadura), Spain (Galicia), Spain
(Valencian region), Sweden, the Netherlands, UK (England/Northern Ireland/Wales) and UK (Scotland). Unadjusted survival probabilities were calculated using the
Kaplan–Meier method, and adjusted survival probabilities using the Cox regression model.
aAnalyses were adjusted using fixed values: age (67 years), sex (63% men) and cause of kidney failure (24% DM, 19% hypertension/renal vascular disease, 11% glomeru-
lonephritis and 46% other causes).
bAnalyses were adjusted using fixed values: age (50 years), sex (63% men) and cause of kidney failure (14% DM, 10% hypertension/renal vascular disease, 23% glomeru-
lonephritis and 53% other causes).
FIGURE 13: Survival of patients starting HD and PD between 2009 and 2013 from Day 91 (A) and patients receiving a first kidney transplant from a living or deceased do-
nor between 2009 and 2013 (B). Survival on dialysis was censored for kidney transplantation, and adjusted using fixed values for age (67 years), sex (63% men) and cause
of kidney failure (24% DM, 19% hypertension/renal vascular disease, 11% glomerulonephritis and 46% other causes). Survival after kidney transplantation was adjusted
using fixed values for age (50 years), sex (63% men) and cause of kidney failure (14% DM, 10% hypertension/renal vascular disease, 23% glomerulonephritis and 53%
other causes). These figures are based on the data from the following registries providing individual patient data: Austria, Belgium (Dutch-speaking), Belgium (French-
speaking), Bosnia and Herzegovina, Denmark, Finland, France, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country),
Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Galicia), Spain (Community of Madrid), Spain
(Valencian region), Sweden, the Netherlands, UK (England/Northern Ireland/Wales) and UK (Scotland).
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FIGURE 14: Expected remaining lifetimes of prevalent dialysis and kidney trans-
plant patients (Cohort 2013–17) and the general population (Cohort 2013–17), by
age. This figure is based on data from the following registries providing individ-
ual patient data: Austria, Belgium (Dutch-speaking), Belgium (French-speaking),
Bosnia and Herzegovina, Denmark, Finland, France, Greece, Iceland, Norway,
Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque Country),
Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain
(Catalonia), Spain (Extremadura), Spain (Galicia), Spain (Community of Madrid),
Spain (Valencian region), Sweden, the Netherlands and the UK (all countries).
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